NME Goal Dates Sparse In Late 2007: Third Year Of Low NME Count Likely
Executive Summary
Only three NDAs for new molecular entities have user fee goal dates in the remainder of 2007, which implies a marked slow-down in the pace of NME actions after FDA's busy October (see chart: "1Remaining Candidates For The NME Class Of 2007")
You may also be interested in...
FDA First-Cycle Approval Rate Is Silver Lining In Cloud Of Low NME Count
Three-quarters of the new molecular entities cleared by FDA in 2007 were approved on the first review cycle, a high for this decade and a positive note to counterbalance the record low number of NMEs approved
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.